Skip to main content

Nio Stock Finally Has Some Positive Near-Term Triggers

Nio Stock Finally Has Some Positive Near-Term TriggersNio (NYSE:NIO) has been unimpressive for the most part of the year. From March 2019 highs of $10.16, the stock slumped by 87% to $1.32 in the beginning of October. In percentage terms, there has been a big relief rally with Nio stock currently higher by about 92%. While Nio has fundamental problems, I believe that the stock can continue to rally in the foreseeable future.Source: xiaorui / Shutterstock.com From a macro perspective, the first phase of the trade deal between the United States and China has been reached. This is a key positive trigger as it can boost China's GDP growth in 2020 and beyond. Weak sales in the broad automotive industry can reverse if GDP growth gains traction. Stronger GDP growth will offset the negative impact of phasing out of subsidies for electric vehicles.From an industry perspective, China recently raised sales target for electric cars to about 25% by 2025. Currently, electric cars account for just 5% of automotive sales in China. Clearly, the government has set an ambitious target for the next five years. This is likely to benefit Nio, among other players in the industry.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Positive on Third Quarter 2019 ResultsNio will announce 3Q19 results on December 30. I believe that the stock can trend higher when numbers are announced. Nio has reported healthy delivery numbers for 3Q19 with deliveries increasing by 35.1% as compared to 2Q19. * 7 Stocks to Buy to Get 2020 Started the Right Way It is also important to note that strong delivery has been reported for October and November. The company expects this positive momentum to sustain. Therefore, the second half of 2019 is likely to be better than the first half.Gross margins are likely to remain negative in the coming quarters, but sustained volumes growth is critical for cash flows to turn positive. If volume growth is maintained well into 2020, Nio stock is positioned for further upside. Cash Burn Remains a ConcernNio has been working on cutting costs and increasing sales volumes to reduce the cash burn. However, I don't see positive cash flows anytime soon. This is one factor that will worry the markets even as near-term sentiment seems positive.Nio has ample cash buffer for 2020, but it seems certain that the company will require additional financing beyond the next 12-months. Therefore, dilution worries will impact the long-term trend for the stock.This is particularly true in a market that has immense growth potential and fierce competition, at the same time. It is worth noting that Tesla (NASDAQ:TSLA) believes that it can fund expansions through internal cash flows.Nio is far from reaching that point and will have to compete with Tesla and Ford Motor (NYSE:F), among others. These large players have ample cash buffer and positive cash flows to navigate an extended period of cash burn.It was recently reported that Nio will be launching another SUV in China. This is to compete with the likes of Mercedes-Benz and Tesla. As competition remains intense, there will continue to be investments in R&D and new launches.As an example, Nio reported R&D expense of $189.4 million, which was 70% higher than 2Q18. The key reason was rigorous testing activities of ES6 before its mass production. Therefore, innovation and competition would imply new model launches and that will impact margins. Overall, turning cash flow positive is a big challenge for Nio and investors will continue to look for answers. Even as the respite rally sustains in the near-term. My Final Thoughts on Nio StockThe Nio stock price is significantly higher from all-time-lows and the rally might continue into 2020. However, it is too early to assume that the company is out of the woods. Investors who have bought at lower levels can consider some profit booking after 3Q19 results.Chinese electric vehicle market has the potential to grow at a healthy pace in the next five years. From that perspective, several players can be absorbed in the market. However, China's EV market is in a bubble phase and many companies will go bankrupt or will be acquired in the coming years. Nio will need something very special to keep going over the next three to five years.As of this writing, Faisal Humayun did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 2019 Losers That Will Be 2020 Winners * 7 Safe Dividend Stocks for Investors to Buy Right Now * 5 Artificial Intelligence Stocks to Consider The post Nio Stock Finally Has Some Positive Near-Term Triggers appeared first on InvestorPlace.




from Yahoo Finance https://ift.tt/37j561i

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be